Ultra-Rapid Genomic Test Cuts Brain Tumor Diagnosis Time From Weeks to Hours

The UK's National Health Service (NHS) has launched a major pilot for an ultra-rapid genomic test that cuts the time required to diagnose a brain tumor from up to eight weeks to under two hours. The technology allows neurosurgeons to identify the exact genetic signature of a cancer while the patient is still on the operating table, fundamentally altering how brain surgeries are performed and how quickly targeted treatments can begin. Primary brain tumors remain the single biggest cancer killer of children and adults under 40 in the UK, making the speed of diagnosis a critical factor in patient survival.[1][2][3]

The diagnostic tool relies on a mechanism called nanopore genetic sequencing, shifting the analysis from visual inspection to molecular profiling. During a biopsy or tumor resection, a small tissue sample is extracted and placed directly into a shoebox-sized sequencing machine manufactured by Oxford Nanopore. Inside the device, individual DNA molecules are pulled through microscopic holes—nanopores—and the system measures minute disruptions in an electrical current to read the genetic code in real time. This bypasses the need for the lengthy chemical preparation required by traditional laboratory sequencing.[1][2]

That raw genetic data is then processed by a specialized software platform known as ROBIN (Rapid Nanopore Brain Intraoperative Classification). Developed by researchers at the University of Nottingham and Nottingham University Hospitals NHS Trust, the software analyzes the tumor's DNA and classifies the specific cancer type in roughly 20 minutes. The underlying research for the system, which was published in the journal Neuro-Oncology in 2025, demonstrated that the algorithm could accurately match the genomic signatures of tumors against known databases faster than any previous method.[2]

The speed of the ROBIN system solves a major biological and logistical bottleneck in neuro-oncology. Brain tumors are notoriously difficult to treat because there are more than 100 distinct types, ranging from slow-growing benign masses to highly aggressive cancers like glioblastoma. Because each variant responds differently to specific regimens of radiation and chemotherapy, oncologists cannot finalize a treatment plan until the exact molecular type is known.[2]

Traditionally, the diagnostic process requires an MRI or CT scan, followed by a surgical biopsy. The extracted tissue is then sent away to a pathology lab, where it is chemically treated, sliced, and examined under a microscope by specialists. For the more than 12,000 people diagnosed with brain tumors in the UK annually, that conventional process means waiting up to six to eight weeks in agonizing uncertainty for a definitive answer, during which time aggressive tumors can continue to grow.[1][2]

By shrinking that diagnostic window to less than two hours, the rapid test provides actionable data mid-surgery. If the sequencing reveals a highly aggressive tumor, neurosurgeons can opt to remove a wider margin of tissue immediately, knowing the risks are justified by the cancer's severity. Conversely, if the tumor is identified as a less aggressive variant, the surgical team can prioritize preserving healthy brain matter, minimizing the risk of permanent neurological damage to the patient.[2][3]

"The ability to have detailed information about the tumour at the point when decisions are being made in the operating theatre is gamechanging," said Stuart Smith, a consultant neurosurgeon at Nottingham University Hospitals NHS Trust who co-led the development of the test. He noted that the immediate feedback saves valuable time for patients who "potentially are being told they don't have time on their side," allowing surgical teams to optimize their approach before the patient even wakes up from anesthesia.[1]

Beyond the operating room, the rapid turnaround accelerates the next phases of post-operative care. Patients can begin targeted radiotherapy or chemotherapy within days rather than months, closing the gap where the disease might otherwise advance unchecked. Furthermore, the precise genetic profiling helps match patients to suitable clinical trials much earlier, as many experimental treatments require a confirmed molecular target before a patient is eligible to enroll—opportunities that are sometimes missed when a diagnosis takes two months to arrive.[1][2]

"For people with suspected brain tumours, getting the right diagnosis quickly can feel like a race against time, while waiting weeks for answers can be agonising for them and their families," said Professor Frankie Swords, the NHS medical director. She described the rapid genomic test as a "huge leap forward" that possesses the potential to completely transform the standard of care for neuro-oncology patients across the health service.[1][2]

Following its initial success in Nottingham, NHS England is rolling out the pilot program to five specialist centers across the country in September 2026. The initial expansion includes hospital trusts in Newcastle and Birmingham, as well as London's Great Ormond Street and King's College hospitals. If the pilot proves successful at integrating the technology into routine surgical workflows, the NHS plans to eventually bring the rapid testing to sites in Bristol, Oxford, Leeds, and Manchester.[1]